FAQ: HeartBeam Inc. Q2 2025 Results Conference Call and Business Updates

What is the purpose of the HeartBeam Inc. conference call on August 13, 2025?

The conference call is to discuss HeartBeam Inc.’s second-quarter results for the period ended June 30, 2025, and provide updates on regulatory initiatives, commercial-readiness activities, and anticipated milestones.

Who will host the HeartBeam Inc. conference call?

CEO Robert Eno and CFO Timothy Cruickshank will host the call, which will include a question-and-answer session.

How can I access the full press release about the conference call?

The full press release can be viewed at https://ibn.fm/9MZKX.

What is HeartBeam Inc.’s focus in the medical technology field?

HeartBeam Inc. is focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, including developing the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions.

What makes HeartBeam Inc.’s technology unique?

Its platform technology is designed for portable devices that deliver actionable heart intelligence outside of a medical facility, aiming to redefine the future of cardiac health management.

How many patents does HeartBeam Inc. hold?

The company holds 13 U.S. and 4 international-issued patents related to technology enablement.

Where can I find the latest news and updates about HeartBeam Inc.?

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.

What is BioMedWire’s role in the biotechnology and life sciences sectors?

BioMedWire is a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, providing access to a vast network of wire solutions, article and editorial syndication, and social media distribution.